You’re not alone: one in four of us will be affected by a mental health disorder in our lifetime. We are determined to continue to increase our understanding of mental illness by supporting and engaging with you, the patient, through open dialogue and innovative treatments.
We want to reduce the burden, disability and devastation caused by serious neuropsychiatric and neurodegenerative diseases.
Our mission is to develop new solutions and innovations that not only improve, but transform, the lives of people living with mental illness.
We are committed to improving the way in which mental health disorders are prevented, diagnosed and treated in order to change the lives of people living with mental illness.
Our Commitment to Patients
Our ultimate responsibility remains with our patients.
One in four of us will be affected by a mental health disorder in our lifetime. We recognise the heartbreak that these conditions can cause for those affected and their loved ones. The burden and impact of mental illness is vast.
That’s why we need an on-going dialogue with patients and their carers to enhance our understanding of living with mental health conditions. Because it’s through understanding mental illness from the perspective of those living with these conditions that we’re better able to help.
We work with around 30 patient groups and organisations across Europe to continually build on our understanding of living with mental health conditions. We ensure that the insights we gather through open and ongoing dialogue with patients are incorporated into disease area strategies.
“As Dr Paul Janssen said so many times, ‘the patients are waiting’. And our ultimate responsibility remains with our patients.”
“We recognise the heartbreak that mental health conditions can cause for those affected and their loved ones. That’s why we are having an ongoing dialogue so that we create solutions for patients, with patients.”
EMEA Therapeutic Area Leader, Neuroscience IDV & PAH
Innovation remains at our core and we continue to work on finding new ways to reduce the burden of disease for those affected by mental illness.
We want to use breakthrough technologies to drive earlier, more accurate diagnoses, and to predict more precisely how patients will respond to treatments.
Right now, we’re exploring digital technologies that anticipate relapses in schizophrenia and major depressive disorders. We’re also excited that we have 22 new single molecular entities under investigation in our neuroscience research and development department.
Across Neuroscience, Janssen researchers are exploring the emerging science in neurodegenerative and neuroinflammatory disorders, including synaptic plasticity and cellular resilience. We’re also seeking to use breakthrough technologies in imaging, genomics and associated biomarkers.
We can’t do this alone – to advance our work, we look for partners and collaborators who share our goals.
Our strategy is to harness the best science in the world, whether from our own laboratories or through strategic relationships and collaborations with academic institutions, biotech and other pharmaceutical companies.
We have successfully established many partnerships through creative and innovative deal structures, and we are continuously looking for new ways to collaborate in our core areas of interest. We actively pursue licensing, acquisition, academic partnership and public-private partnership opportunities as well as other innovative business structures.
Every year the Johnson & Johnson Family of Companies enters into more than 200 collaborations with external organisations. We do this to conduct research, harness new technologies, pursue scientific innovations, improve education and enhance the way we work.Learn more about collaborations
40 million people across the EU are affected with depression. It’s the leading cause of disability and disease burden worldwide according to the World Health Organization, with a high unmet need. Which means there is a lot more work to be done.
Achieving response and remission with treatment in major depressive disorder (MDD) requires time and effort, prolonging patient suffering and reducing expectations from treatment. Treatment has changed very little over 30 years, leading to a resigned acceptance of suboptimal outcomes for patients.
We’re committed to using emerging science to develop novel therapies for the treatment of severe mood disorders. New approaches to treatment are needed, which will offer an improved response in patients.
1 in 4 people will be affected by mental health problems, such as depression, during their lives. 40 million people across Europe are estimated to be living with one of the more severe types of depression, known as major depressive disorder or MDD., 
Breaking Depression aims to raise awareness of the challenges of living with different types of depression, including MDD. The campaign has been started by Janssen, with support from the Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) and the European Federation of Associations of Families of People with Mental Illness (EUFAMI).
It explores the reality of living with MDD through kintsugi, the Japanese art of ‘golden joinery’: repairing broken objects with lacquer dusted or mixed with powdered gold. The campaign is centred around eight works of kintsugi art, inspired by stories from people living with MDD.Pledge your support
At Janssen, we’ve led the way in the development of simplified and innovative treatments for patients with schizophrenia. But the challenge of schizophrenia is not solved completely.
World Health Report. Mental disorders affects one in four people. Available at: https://www.who.int/whr/2001/media_centre/press_release/en/. Accessed: October 2020.
WHO. Model List of Essential Medicines. Available at: https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf?ua=1 Accessed: November 2020.
Janssen. 2019. Psychiatry: Mood Disorders Portfolio. Data on file. PSY/DOF/MAY2019/EMEA001.
 Johnson & Johnson Innovation. Johnson & Johnson Innovation Announces 17 Collaborations With Focus on Advancing Global Healthcare Through Transformational Science and Technologies. Available at: https://jnjinnovation.com/sites/jji/files/downloads/news/johnson_johnson_innovation_announces_.h_focus_on_advancing_global_healthcare.pdf.pdf. Accessed: November 2020.
 WHO. Depression. Available at: https://www.euro.who.int/en/health-topics/noncommunicable-diseases/mental-health/areas-of-work/depression. Accessed: November 2020.
Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.
WHO. Depression and Other Common Mental Health Disorders. Available at: www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/. Accessed: November 2020.
 Abi-Dargham A. Schizophrenia: overview and dopamine dysfunction. J Clin Psychiatry. 2014;75(11):e31. doi:10.4088/JCP.13078tx2c.
 Athanasopoulou, C. et al. An analysis of online health information on schizophrenia or related conditions: a cross-sectional survey. BMC Medical Informatics and Decision Making. 2013;13(98).
 Theodoridou A. & Rössler W. Disease Burden and Disability-Adjusted Life Years Due to Schizophrenia and Psychotic Disorders. In: Preedy V.R., Watson R.R. (eds) Handbook of Disease Burdens and Quality of Life Measures. Springer, New York, NY. 2010. https://doi.org/10.1007/978-0-387-78665-0_87.
Millier A, et al. Humanistic burden in schizophrenia: A literature review. J Psych Res 2014;54:85–93.
Bitter I, et al. Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study. Eur Psychiatry 2017;45:97–103.
Flycht L, et al. Determinants of subjective and objective burden of informal caregiving of patients with psychotic disorders. Int J Soc Psychiatry 2015;61(7):684–692.